Abstracts Archive - Page 1358 of 2607 - ACR Meeting Abstracts

Abstract Number: 2577 • 2018 ACR/ARHP Annual Meeting
Long-Term Effect of Ixekizumab on Patient-Reported Outcomes in Patients with Psa and Inadequate Response to TNF Inhibitors: 2-Year Follow-up from a Phase 3 Study
Anthony Turkiewicz¹, Amanda M. Gellett², Lisa Kerr², Julie Birt² and Jordi Gratacos³, ¹Rheumatology Associates, Birmingham, AL, ²Eli Lilly and Company, Indianapolis, IN, ³Rheumatology, Hospital Parc Taulí, Sabadell - Barcelona, Spain
Background/Purpose: PsA is a chronic and complex inflammatory disease with both articular and extra-articular symptoms, including joint pain, enthesitis, dactylitis, fatigue, and skin and nail…
Abstract Number: 2578 • 2018 ACR/ARHP Annual Meeting
Exposure Response Analyses to Describe the Relationship between Ixekizumab Concentrations and Acr Responses in Psoriatic Arthritis Patients
C. Steven Ernest II, Nieves Velez de Mendizabal and Leijun Hu, Eli Lilly and Company, Indianapolis, IN
Background/Purpose: Ixekizumab is a high-affinity monoclonal antibody that selectively targets interleukin (IL)-17A. It has been approved to treat adult patients with moderate-to-severe plaque psoriasis and…
Abstract Number: 2579 • 2018 ACR/ARHP Annual Meeting
Ixekizumab Treatment Significantly Improves Enthesitis and Dactylitis in Patients with Active Psoriatic Arthritis: Results from Two Phase 3 Trials
Dafna D Gladman¹, Ana-Maria Orbai², Gaia Gallo³, Julie Birt³, Suchitrita Rathmann³ and Helena Marzo-Ortega⁴, ¹Rheumatology, University of Toronto, Toronto, ON, Canada, ²Johns Hopkins University School of Medicine, Baltimore, MD, ³Eli Lilly and Company, Indianapolis, IN, ⁴NIHR LBRC, LTHT and LIRMM, University of Leeds, Leeds, United Kingdom
Background/Purpose: Ixekizumab (IXE), an IL-17A antagonist, is approved in the USA for the treatment of PsA including patients (pts) with pre-existing enthesitis or dactylitis. Previous…
Abstract Number: 2580 • 2018 ACR/ARHP Annual Meeting
Predicting Treatment Persistence and Non-Persistence of Newly Initiated TNF Inhibitor Therapy in Ankylosing Spondylitis Patients: A Gender Comparison
Theresa Hunter¹, Atul A. Deodhar², Rebecca Bolce¹, Krista Schroeder¹ and David Sandoval Calderon¹, ¹Eli Lilly and Company, Indianapolis, IN, ²Oregon Health & Science U, Portland, OR
Background/Purpose: The purpose of this study was to compare treatment patterns in the 2 years following the initiation of TNF inhibitor (TNFi) in AS patients.Methods:…
Abstract Number: 2581 • 2018 ACR/ARHP Annual Meeting
Comparing Treatment Patterns of Non-Radiographic Axial Spondyloarthritis Patients in the United States and Europe
Theresa Hunter¹, David Sandoval Calderon¹, Steve Lobosco², Rachel Moon², Gary Milligan³ and Rebecca Bolce¹, ¹Eli Lilly and Company, Indianapolis, IN, ²Adelphi Real World, Macclesfield, United Kingdom, ³Adelphi Real World, Macclesfield,, United Kingdom
Background/Purpose: To compare TNF inhibitor (TNFi) use and switching patterns among patients with nr-axSpA in the United States (US) and Europe (EU). Methods: Data from…
Abstract Number: 2582 • 2018 ACR/ARHP Annual Meeting
Post-Marketing Safety of Secukinumab in Adult Patients with Psoriasis, Psoriatic Arthritis and Ankylosing Spondylitis: Cumulative Analysis across >96,000 Patient-Treatment Years Exposure
Atul A. Deodhar¹, Dafna D Gladman², Iain B. McInnes³, Filip van Den Bosch⁴, Abhijit Shete⁵, Ruquan You⁶, Samina Hussain⁷ and Jorge Safi⁸, ¹Oregon Health & Science University, Portland, OR, ²Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada, ³Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, United Kingdom, ⁴Rheumatology, Ghent University Hospital and VIB Ghent University, Gent, Belgium, ⁵Novartis Pharma AG, Basel, Switzerland, Basel, Switzerland, ⁶Shanghai Novartis Trading Limited, Shanghai, China, ⁷Novartis Healthcare Private Limited, Hyderabad, India, ⁸Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, East Hanover, NJ
Background/Purpose: Secukinumab, a fully human monoclonal IgG1 antibody that selectively neutralizes IL-17A, is currently approved in >75 countries for use in psoriasis /psoriatic arthritis and…
Abstract Number: 2583 • 2018 ACR/ARHP Annual Meeting
Secukinumab Provides Early and Sustained Improvements in Health-Related Quality of Life in Patients with Ankylosing Spondylitis: A Pooled Analysis from the Secukinumab Phase 3 Trial Program
Atul A. Deodhar¹, Annelies Boonen², Gianfranco Ferraccioli³, Filip van Den Bosch⁴, David Martinez⁵, Brian Porter⁶, Abhijit Shete⁷, Nicolas Scheuer⁷, Isabelle Gilloteau⁷ and Vibeke Strand⁸, ¹Oregon Health & Science University, Portland, OR, USA, Portland, OR, ²Department of Rheumatology, Maastricht University Medical Center, Maastricht, The Netherlands, Maastricht, Netherlands, ³Catholic University School of Medicine, Rome, Italy, Rome, Italy, ⁴Ghent University Hospital, Ghent, Belgium, Ghent, Belgium, ⁵RTI Health Solutions, Research Triangle Park, NC, USA, Research Triangle Park, NC, ⁶Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, East Hanover, NJ, ⁷Novartis Pharma AG, Basel, Switzerland, Basel, Switzerland, ⁸Stanford University, Palo Alto, CA, USA, Palo Alto, CA
Background/Purpose: Secukinumab has demonstrated rapid and sustained improvements in the signs and symptoms of ankylosing spondylitis (AS) across multiple randomized controlled trials. Using pooled data…
Abstract Number: 2584 • 2018 ACR/ARHP Annual Meeting
Low Incidence of Both New-Onset and Flares of Uveitis in Secukinumab-Treated Patients with Ankylosing Spondylitis: Clinical Trial and Post-Marketing Safety Analysis
Atul A. Deodhar¹, Corinne Miceli-Richard², Xenofon Baraliakos³, Helena Marzo-Ortega⁴, Dafna D Gladman⁵, Ruvie Martin⁶, Jorge Safi⁷, Brian Porter⁷ and Abhijit Shete⁸, ¹Oregon Health & Science University, Portland, OR, ²Rheumatology Department, Paris Descartes University, Paris, France, ³Ruhr-University Bochum, Herne, Germany, ⁴NIHR LBRC, LTHT and LIRMM, University of Leeds, Leeds, United Kingdom, ⁵Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada, ⁶Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁷Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, East Hanover, NJ, ⁸Novartis Pharma AG, Basel, Switzerland, Basel, Switzerland
Background/Purpose: Uveitis, a common extra-articular manifestation of spondyloarthritis (SpA), has an estimated prevalence of 33.2% in patients with ankylosing spondylitis (AS), which increases with duration…
Abstract Number: 2585 • 2018 ACR/ARHP Annual Meeting
Secukinumab Immunogenicity in Patients with Psoriatic Arthritis and Ankylosing Spondylitis during a 52-Week Treatment Period
Atul A. Deodhar¹, Dafna D Gladman², Iain B. McInnes³, Vibeke Strand⁴, Mengyuan Ren⁵, Sebastian Spindeldreher⁶, Luminita Pricop⁷, Brian Porter⁷, Jorge Safi⁷, Abhijit Shete⁸ and Gerard Bruin⁶, ¹Oregon Health & Science University, Portland, OR, ²Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada, ³Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, United Kingdom, ⁴Division of Immunology/Rheumatology, Stanford University, Palo Alto, CA, ⁵Novartis Pharmaceuticals, Shanghai, China, ⁶Novartis Institutes for BioMedical Research, Basel, Switzerland, ⁷Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, East Hanover, NJ, ⁸Novartis Pharma AG, Basel, Switzerland, Basel, Switzerland
Background/Purpose: Secukinumab, a fully human monoclonal IgG1 antibody (mAb) that selectively targets IL-17A, is efficacious for the treatment of psoriasis, psoriatic arthritis (PsA) and ankylosing…
Abstract Number: 2586 • 2018 ACR/ARHP Annual Meeting
Changes in Lymphocytes and Lymphocyte Subsets in Tofacitinib-Treated Patients with Psoriatic Arthritis
Gerd R. Burmester¹, William FC Rigby², Ernest Choy³, Peter Nash⁴, Kevin Winthrop⁵, Philip J. Mease⁶, Pamela Young⁷, Thijs Hendrikx⁷, Cunshan Wang⁸, Sujatha Menon⁸ and Daniela Graham⁸, ¹Charité – University Medicine Berlin, Berlin, Germany, ²Geisel School of Medicine at Dartmouth, Lebanon, NH, ³Cardiff University School of Medicine, Cardiff, United Kingdom, ⁴University of Queensland, Brisbane, Australia, ⁵Oregon Health and Science University, Portland, OR, ⁶Swedish Medical Center and University of Washington, Seattle, WA, ⁷Pfizer Inc, Collegeville, PA, ⁸Pfizer Inc, Groton, CT
Background/Purpose: Tofacitinib is an oral Janus kinase (JAK) inhibitor for the treatment of psoriatic arthritis (PsA). Cytokines involved in lymphocyte development, function, and homeostasis signal…
Abstract Number: 2587 • 2018 ACR/ARHP Annual Meeting
The Impact of Tumor Necrosis Factor Inhibitors on Diabetes Mellitus Among Patients with Inflammatory Arthritis
Santhi Mantravadi¹, Michael D. George² and Alexis Ogdie³, ¹Department of Clinical Pharmacology, Division of Rheumatology, Jefferson University School of Medicine, University of Pennsylvania, Philadelphia, PA, ²Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, ³Medicine/Rheumatology and Epidemiology, University of Pennsylvania, Philadelphia, PA
Background/Purpose: Tumor necrosis factor (TNF) is a key inflammatory cytokine in the pathogenesis of psoriatic arthritis (PsA), RA, ankylosing spondylitis (AS), and diabetes mellitus (DM). …
Abstract Number: 2588 • 2018 ACR/ARHP Annual Meeting
Baseline Pain Severity As a Predictor of Pain Improvement Following Treatment with Tofacitinib in Psoriatic Arthritis
Alexis Ogdie¹, Kurt de Vlam², Andrew G Bushmakin³, Joseph C Cappelleri³, Philip J. Mease⁴, Roy Fleischmann⁵, Peter C. Taylor⁶, Valderilio F Azevedo⁷, Lara Fallon⁸, Anna Maniccia⁹ and John Woolcott¹⁰, ¹University of Pennsylvania, Philadelphia, PA, ²UZ Leuven, Leuven, Belgium, ³Pfizer Inc, Groton, CT, ⁴Swedish Medical Center and University of Washington, Seattle, WA, ⁵University of Texas Southwestern Medical Center, Dallas, TX, ⁶University of Oxford, Oxford, United Kingdom, ⁷Universidade Federal do Paraná, Curitiba, Brazil, ⁸Pfizer Canada, Montreal, QC, Canada, ⁹Pfizer Inc, New York, NY, ¹⁰Pfizer Inc, Collegeville, PA
Background/Purpose: Pain is a core domain of psoriatic arthritis (PsA), and it is recommended that all randomized controlled trials (RCTs) in patients (pts) with PsA…
Abstract Number: 2589 • 2018 ACR/ARHP Annual Meeting
Clinical Characteristics and Treatment Profile of Patients with Psoriatic Arthritis Who Initiated Secukinumab and Other Biologics: Results from the Corrona Psoriatic Arthritis/Spondyloarthritis (PsA/SpA) Registry
Alexis Ogdie¹, Mei Liu², Sabrina Rebello³, Meghan Glynn², Peter Hur⁴ and Philip J. Mease⁵, ¹Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, ²Corrona, LLC, Waltham, MA, ³Corrona, LLC, Southborough, MA, ⁴Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA, East Hanover, NJ, ⁵Swedish Medical Center and University of Washington, Seattle, WA
Background/Purpose: Few real-world studies have characterized patients with psoriatic arthritis (PsA) who initiate secukinumab. This study described characteristics of patients who initiated secukinumab and other…
Abstract Number: 2590 • 2018 ACR/ARHP Annual Meeting
Descriptive Comparisons of the Impact of Apremilast and Methotrexate Monotherapy in Patients with Oligoarticular Psoriatic Arthritis in the Corrona Psoriatic Arthritis/Spondyloarthritis Registry
Alexis Ogdie¹, Mei Liu², Meghan Glynn², Kelechi Emeanuru², Leslie R Harrold³, Sven Richter⁴, Benoit Guerette⁴ and Philip J. Mease⁵, ¹University of Pennsylvania, Philadelphia, PA, ²Corrona, LLC, Waltham, MA, ³University of Massachusetts Medical School, Worcester, MA, ⁴Celgene Corporation, Summit, NJ, ⁵Swedish Medical Center and University of Washington School of Medicine, Seattle, WA
Background/Purpose: The effectiveness of therapies has rarely been studied in the subpopulation of patients with oligoarticular psoriatic arthritis (PsA). The objective of this study was…
Abstract Number: 2591 • 2018 ACR/ARHP Annual Meeting
Real-World Use of Secukinumab in Axial Spondyloarthritis: First Year Data from the Czech National Registry
Herman F Mann¹, Jakub Zavada², Lucie Nekvindová³, Zlatuse Kristkova³, Pavel Horák⁴, Jiri Vencovsky¹ and Karel Pavelka², ¹Institute of Rheumatology and Department of Rheumatology, 1st Faculty of Medicine, Charles University, Czech Republic, Prague 2, Czech Republic, ²Institute of Rheumatology and Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, ³Institute of Biostatistics and Analyses, Ltd., spinoff company of Masaryk University, Brno, Czech Republic, ⁴IIIrd Department of internal Medicine, Faculty of Medicine and Dentistry, Palacký University, Olomouc, Czech Republic
Background/Purpose: Until recently, inhibitors of TNF (TNFi) had been the only bDMARD treatment option for patients with axial spondyloarthritis (AxSpA). This situation changed when anti-interleukin-17A…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].